Sterile Preparations | Varsity Tutors

SECTION 1

Historical Context & Motivation

The history of sterile preparations is inseparable from the broader evolution of germ theory and the development of injectable dosage forms. In the nineteenth century, physicians began administering drugs by injection without a thorough understanding of microbial contamination, leading to devastating infections and septicemia in patients. As Louis Pasteur and Robert Koch established the principles of microbiology, it became clear that any preparation introduced directly into the bloodstream, cerebrospinal fluid, or other sterile body compartments had to be free of viable microorganisms. This realization catalyzed the development of aseptic manufacturing processes in hospital pharmacies and, eventually, formal regulatory oversight of compounding practices.

1860s

Germ Theory & Pasteurization

Louis Pasteur's experiments disprove spontaneous generation, establishing that microorganisms cause contamination and disease—forming the scientific rationale for sterilization of pharmaceutical products.

1900s

First Hospital IV Preparations

Early intravenous solutions of saline and glucose are compounded in hospital pharmacies under rudimentary aseptic conditions, marking the birth of institutional sterile compounding.

1971

HEPA Filtration & Laminar Airflow

High-efficiency particulate air (HEPA) filters and laminar airflow workbenches become standard in pharmacy cleanrooms, dramatically reducing microbial and particulate contamination.

2004

USP Chapter ⟨797⟩ Published

The United States Pharmacopeia publishes Chapter ⟨797⟩, the first enforceable national standard for compounding sterile preparations in pharmacies, establishing risk categories, environmental controls, and personnel competencies.

2023

Revised USP ⟨797⟩ Implementation

After years of revision, the updated USP ⟨797⟩ introduces a two-category system (Category 1 and Category 2) with refined beyond-use date assignments and enhanced environmental monitoring requirements.

The fundamental question that sterile compounding addresses is deceptively simple: how can pharmacists reliably produce preparations that are free of microbial contamination, pyrogens, and particulate matter when the drug product must bypass the body's natural defense barriers? The answer involves an integrated system of environmental engineering, personnel training, quality assurance testing, and rigorous documentation—all codified in standards such as USP ⟨797⟩ and reinforced by state boards of pharmacy and accrediting organizations.

SECTION 2

Core Principles & Definitions

Sterile compounding rests on several foundational principles that collectively ensure patient safety. A compounded sterile preparation (CSP) is any dosage form that must be sterile when administered to a patient—this includes intravenous admixtures, ophthalmic solutions, intrathecal injections, and irrigating solutions, among others. Unlike commercially manufactured products that undergo terminal sterilization in validated autoclaves or are produced under rigorously validated aseptic conditions on an industrial scale, CSPs are typically prepared in pharmacy cleanrooms where the pharmacist or technician serves as both compounder and quality assurance agent. The overarching goal is to deliver a preparation that is sterile, non-pyrogenic, free of particulates, and of the correct identity, potency, and purity.

Aseptic Technique

The set of practices used to prevent microbial contamination during compounding, including proper gowning, hand hygiene, disinfection of surfaces, and manipulation of sterile components within ISO Class 5 airflow.

ISO Classified Environments

Cleanrooms and engineering controls rated by airborne particle counts. The primary engineering control (PEC) must provide ISO Class 5 air at the critical site; surrounding buffer and ante areas must meet ISO Class 7 and ISO Class 8 standards, respectively.

Beyond-Use Dating (BUD)

The date and time after which a CSP may no longer be used. BUDs are assigned based on risk category, storage conditions, and whether sterility testing has been performed—distinct from manufacturer expiration dates.

USP ⟨797⟩ Risk Categories

The revised USP ⟨797⟩ classifies CSPs as Category 1 (shorter BUDs, fewer testing requirements) or Category 2 (extended BUDs requiring more stringent environmental controls and sterility testing).

Personnel Competency

All personnel must demonstrate competency in aseptic technique through initial and ongoing media-fill testing, garbing validation, and written assessments—repeated at defined intervals per USP ⟨797⟩.

✦ KEY TAKEAWAY

Think of a sterile compounding cleanroom like a surgical operating theater. Just as a surgeon scrubs in, dons sterile gowns and gloves, and operates under laminar airflow to prevent wound infections, a pharmacy technician garbs, sanitizes, and compounds within a controlled environment to prevent contamination of the CSP. Every layer of protection—from HEPA filtration to disinfectant wipe-downs—functions as a barrier between the patient's bloodstream and the microorganisms that inhabit the outside world.

SECTION 3

Visual Explanation — Cleanroom Layout & Airflow

This diagram illustrates the three concentric zones of a compliant sterile compounding facility: the ante area (ISO Class 8) where personnel garb, the buffer room (ISO Class 7) maintained under positive pressure with HEPA-filtered supply air, and the primary engineering control (PEC) providing ISO Class 5 unidirectional airflow at the critical compounding site. Note the particle count limits at each stage, decreasing by orders of magnitude as one approaches the critical zone.

The physical layout of a sterile compounding suite enforces a unidirectional workflow that progressively reduces the bioburden on both personnel and materials. Staff enter through the ante area, where they perform hand hygiene, don shoe covers, hair covers, face masks, and finally a sterile gown and gloves before proceeding through the line of demarcation into the buffer room. The positive pressure differential between the buffer room and surrounding areas ensures that air flows outward, preventing unfiltered air from entering. Within the buffer room, the primary engineering control—typically a laminar airflow workbench (LAFW) for non-hazardous drugs or a biological safety cabinet (BSC) for hazardous drugs—provides ISO Class 5 unidirectional airflow directly over the critical site where vials, syringes, and IV bags are manipulated.

SECTION 4

How Sterile Compounding Works — Process & Controls

Aseptic Technique: Critical Steps

The compounding process begins well before a needle touches a vial. A master formulation record documents the recipe, including ingredient identities, quantities, equipment, and procedures, while the compounding record captures lot-specific data for each batch. The pharmacist verifies the order, confirms compatibility of all ingredients, and assigns a beyond-use date based on the applicable USP ⟨797⟩ category. The technician then garbs according to protocol, disinfects the PEC work surface with sterile 70% isopropyl alcohol (IPA), and introduces only essential materials into the ISO Class 5 environment.

Beyond-Use Date Calculations Under Revised USP ⟨797⟩

Beyond-use dating (BUD) is one of the most testable and clinically significant aspects of sterile compounding on the NAPLEX. The revised USP ⟨797⟩ divides CSPs into two categories based on conditions of preparation, testing performed, and intended storage. Understanding the default BUD limits is essential for both exam success and safe practice.

Default BUD limits under revised USP ⟨797⟩ for Category 1 vs. Category 2 CSPs

Storage Condition	Category 1 BUD	Category 2 BUD
Controlled Room Temperature (20–25 °C)	≤ 12 hours	≤ 4 days
Refrigerated (2–8 °C)	≤ 24 hours	≤ 10 days
Frozen (−25 to −10 °C)	Not addressed (use Cat 2)	≤ 45 days

MILLIOSMOLARITY CALCULATION

mOsm/L = (number of particles) × (mmol/L of solute)

For an IV admixture, calculating the osmolarity helps assess compatibility and safety. For example, NaCl dissociates into 2 particles (Na⁺ + Cl⁻), so a 154 mmol/L NaCl solution yields approximately 308 mOsm/L, which is isotonic with blood.

FLOW RATE CALCULATION

Flow Rate (mL/hr) = Total Volume (mL) ÷ Infusion Time (hr)

When setting up an IV infusion, pharmacists verify that the prescribed flow rate is appropriate. For gravity drip sets: drops/min = (Volume in mL × drop factor) ÷ (Time in minutes). Common drop factors include 10, 15, 20, and 60 gtt/mL.

ALLIGATION ALTERNATE

Parts of Higher = |Desired % − Lower %| ; Parts of Lower = |Higher % − Desired %|

Alligation alternate is used to determine the proportions of two solutions of different concentrations needed to prepare a solution of an intermediate concentration—a common calculation in sterile compounding when diluting or concentrating stock solutions.

SECTION 5

Detailed Breakdown — CSP Types & Sterilization Methods

Sterile preparations encompass a wide variety of dosage forms, each with distinct compounding considerations. Understanding the classification of CSPs and the available sterilization methods is critical for selecting the correct approach to any given preparation.

Overview of sterile preparation types (IV admixtures, ophthalmic/otic, intrathecal/epidural), the four primary sterilization methods (autoclaving, filtration, dry heat, radiation/gas), and the quality testing standards applied to finished CSPs. Note that 0.22 µm filtration is the most common sterilization method in pharmacy compounding for heat-labile drugs, while autoclaving remains the gold standard for terminal sterilization of heat-stable preparations.

Among the sterilization methods depicted, sterile filtration through a 0.22 µm membrane filter is by far the most commonly employed technique in pharmacy compounding. This pore size is designated as bacteria-retentive because it reliably removes bacteria and fungi from solutions, although it does not remove viruses, endotoxins, or prions. When a preparation must be rendered pyrogen-free (depyrogenated), dry heat sterilization at ≥ 250 °C for ≥ 30 minutes is used for glassware and equipment, while the bacterial endotoxin test (BET) per USP ⟨85⟩ confirms acceptably low endotoxin levels in the finished solution. Intrathecal preparations demand the most stringent endotoxin limits because the blood-brain barrier offers no protection against pyrogens once they enter the cerebrospinal fluid.

SECTION 6

Worked Example — Compounding a Vancomycin IV Admixture

Consider the following clinical scenario: a physician orders vancomycin 1,250 mg in 250 mL of 0.9% NaCl to be infused over 2 hours for a patient with a methicillin-resistant Staphylococcus aureus infection. The pharmacy stocks vancomycin 1 g vials, each requiring reconstitution with 20 mL of sterile water for injection (SWFI) to yield a concentration of 50 mg/mL. The CSP will be prepared in a Category 1 cleanroom under standard conditions.

Compounding Vancomycin 1,250 mg in 250 mL NS

Step 1 — Verify the Order & Gather MaterialsConfirm the order for vancomycin 1,250 mg IV in 250 mL NS infused over 2 hours. Gather two vancomycin 1 g vials, one 250 mL bag of 0.9% NaCl, sterile water for injection (20 mL per vial for reconstitution), appropriate syringes (20 mL and 30 mL), needles, and alcohol swabs. Verify expiration dates and lot numbers. Enter data on the compounding record.

Step 2 — Calculate Volume to WithdrawEach vial reconstituted with 20 mL SWFI yields 50 mg/mL. To obtain 1,250 mg total: Volume = 1,250 mg ÷ 50 mg/mL = 25 mL. This requires the full 20 mL from one vial (1,000 mg) plus 5 mL from a second vial (250 mg).

Total volume to withdraw: 25 mL of reconstituted vancomycin

Step 3 — Reconstitute Vials Using Aseptic TechniqueWithin the ISO Class 5 LAFW, swab each vial's rubber stopper with 70% IPA and allow to dry. Draw up 20 mL SWFI per vial and inject into the vancomycin vial. Gently swirl (do not shake vigorously) until the powder is fully dissolved. The resulting solution should be clear.

Step 4 — Withdraw and Transfer to IV BagUsing a new syringe, withdraw the full 20 mL from vial 1. Using a separate syringe, withdraw 5 mL from vial 2. Swab the injection port of the 250 mL NS bag and inject both volumes sequentially. Gently invert the bag several times to ensure homogeneous mixing.

Step 5 — Calculate Final Concentration & Assign BUDFinal volume = 250 mL + 25 mL = 275 mL (unless overfill is removed). Final concentration ≈ 1,250 mg ÷ 275 mL ≈ 4.55 mg/mL. Under Category 1 conditions at controlled room temperature, the BUD is ≤ 12 hours. Calculate the infusion rate: 275 mL ÷ 2 hr = 137.5 mL/hr.

BUD: ≤ 12 hours (CRT, Category 1) | Infusion rate: ≈ 138 mL/hr

Step 6 — Label, Inspect, and VerifyApply a label with patient identifiers, drug name and concentration, total volume, BUD (date and time), storage conditions, and route of administration. Perform a visual inspection for particulates, color changes, and container integrity. A pharmacist must perform a final verification check before the CSP is released for patient administration.

SECTION 7

Comparing PEC Types — Strengths & Limitations

Selecting the correct primary engineering control is a foundational decision in cleanroom design. The three main types—horizontal laminar airflow workbenches (LAFW), biological safety cabinets (BSCs), and compounding aseptic containment isolators (CACIs)—serve different compounding scenarios and offer distinct advantages and trade-offs.

Comparison of Primary Engineering Controls for Sterile Compounding

Feature	Horizontal LAFW	BSC (Class II, Type A2)	CACI / CAI
ISO Class at Critical Site	ISO Class 5	ISO Class 5	ISO Class 5
Hazardous Drug Use	Not permitted	Permitted (HD compounding)	Permitted (HD compounding)
Airflow Direction	Horizontal, toward operator	Vertical downflow; intake at face opening	Varies; fully enclosed system
Operator Protection	None (air flows toward operator)	Inward airflow protects operator	Maximum (sealed barrier)
Buffer Room Requirement	Must be in ISO 7 buffer room	Must be in ISO 7 buffer room (negative pressure for HDs)	May be placed in segregated compounding area if self-decontaminating
Common Use	Non-hazardous IV admixtures, TPN, ophthalmic	Chemotherapy, antiviral, immunosuppressant	HD compounding in limited-space settings

✦ KEY TAKEAWAY

Think of airflow direction as the PEC's 'philosophy of protection.' A horizontal LAFW pushes clean air toward the operator—it protects the product but not the person, which is fine for non-hazardous drugs. A BSC, by contrast, draws room air inward at its face opening, protecting both the product and the operator, making it essential for cytotoxic agents. A CACI encloses the compounding environment entirely, like a sealed glove box, providing the highest level of containment for the most dangerous compounds.

SECTION 8

Connection to Advanced Theory — USP ⟨800⟩ & Hazardous Drug Handling

While USP ⟨797⟩ governs sterile compounding broadly, the handling of hazardous drugs (HDs) requires additional compliance with USP ⟨800⟩, which establishes standards for the receipt, storage, compounding, dispensing, and disposal of hazardous drugs to protect healthcare workers. USP ⟨800⟩ applies to all personnel who handle HDs in any setting, not just those who compound sterile preparations. The chapter mandates a hierarchy of engineering controls, closed-system drug-transfer devices (CSTDs), personal protective equipment, medical surveillance, and environmental monitoring specific to hazardous agents.

USP ⟨797⟩ vs. USP ⟨800⟩: Key Differences

Aspect	USP ⟨797⟩ (Sterile Compounding)	USP ⟨800⟩ (Hazardous Drug Handling)
Scope	All compounded sterile preparations	All hazardous drugs (sterile and non-sterile)
Primary Concern	Patient safety—preventing microbial contamination	Worker safety—minimizing occupational exposure
Room Pressure	Positive pressure buffer room	Negative pressure HD buffer room (externally vented)
PEC Required	LAFW, BSC, or CACI	BSC (Class II or III) or CACI; LAFW prohibited
Supplemental PPE	Standard garbing per ⟨797⟩	Chemotherapy-rated gloves (double), impervious gown, face/eye protection
Environmental Monitoring	Viable and non-viable air/surface sampling	Wipe sampling for HD surface contamination; medical surveillance of workers

The critical intersection between these two chapters occurs when a pharmacist compounds a hazardous sterile preparation—for example, a chemotherapy admixture. In that case, both chapters apply simultaneously: USP ⟨797⟩ dictates the sterile compounding procedures (aseptic technique, BUD assignment, environmental ISO classification), while USP ⟨800⟩ adds the hazardous drug–specific requirements (negative pressure room, externally vented BSC, CSTDs, double chemotherapy gloves, spill management). As pharmacy practice evolves, additional chapters such as USP ⟨825⟩ (radiopharmaceuticals) continue to refine standards for specialized sterile preparations.

💡 NAPLEX TIP

On the NAPLEX, questions frequently test whether you can distinguish between requirements unique to ⟨797⟩ versus ⟨800⟩. Remember: ⟨797⟩ = protect the product (positive pressure, sterility); ⟨800⟩ = protect the worker (negative pressure, containment). When both apply, the more restrictive requirement governs.

SECTION 9

Practice Problems

PROBLEM 1 — CONCEPTUAL

A pharmacy technician is preparing a non-hazardous IV admixture. She is trying to decide between using a horizontal laminar airflow workbench (LAFW) and a biological safety cabinet (BSC). What is the key reason that a BSC is required for hazardous drug compounding but an LAFW is not, even though both provide ISO Class 5 air?

PROBLEM 2 — BASIC CALCULATION

A physician orders ceftriaxone 2 g in 100 mL of D5W to infuse over 30 minutes using a gravity drip set with a drop factor of 20 gtt/mL. Calculate the required drip rate in drops per minute (gtt/min).

PROBLEM 3 — INTERMEDIATE

A hospital pharmacy compounds a batch of 50 vancomycin 1 g in 250 mL NS IV bags under conditions that meet Category 2 requirements per revised USP ⟨797⟩. The bags will be stored in the refrigerator at 2–8 °C. What is the maximum beyond-use date that can be assigned? If ten of these bags are subsequently moved to controlled room temperature (20–25 °C) for distribution, how does the BUD change?

PROBLEM 4 — APPLIED

A compounding pharmacist needs to prepare 500 mL of a 3% NaCl solution for a patient with severe hyponatremia. The pharmacy stocks 0.9% NaCl (500 mL bags) and 23.4% NaCl concentrate (30 mL vials). Using the alligation alternate method, determine how many milliliters of each solution are needed, and explain why this preparation must be treated as a sterile compounding activity.

PROBLEM 5 — CRITICAL THINKING

During a routine environmental monitoring session, a settle plate in the buffer room yields 4 colony-forming units (CFUs), which exceeds the action level of 3 CFUs for an ISO Class 7 area as defined by USP ⟨797⟩. The pharmacy has already compounded 12 CSPs during this monitoring period. Discuss the appropriate corrective actions, the regulatory implications for the 12 CSPs already prepared, and the systemic investigation that should follow. How might this scenario differ if the exceedance had occurred at the ISO Class 5 PEC?

SUMMARY

Lesson Summary

Sterile compounding is a multi-layered discipline in which every element of the process serves to protect the patient from harm. USP ⟨797⟩ establishes the enforceable framework, dividing CSPs into Category 1 (shorter BUDs, standard conditions) and Category 2 (extended BUDs, enhanced testing). The physical infrastructure proceeds through concentric zones of increasing cleanliness: the ante area (ISO Class 8) for garbing, the buffer room (ISO Class 7) maintained under positive pressure, and the primary engineering control (ISO Class 5) where critical manipulations occur. Aseptic technique—the integrated set of hand hygiene, disinfection, and manipulation practices—is the behavioral foundation upon which all of these engineering controls depend.

Key calculations for the NAPLEX include IV flow rate (mL/hr or gtt/min), alligation alternate for mixing concentrations, and beyond-use date assignment based on storage temperature and risk category. When hazardous drugs are involved, USP ⟨800⟩ adds worker-protection requirements including negative pressure rooms, BSCs or CACIs, double chemotherapy gloves, and CSTDs. Sterilization is achieved primarily through 0.22 µm filtration for heat-labile drugs and autoclaving for heat-stable preparations, with quality confirmed through sterility testing (USP ⟨71⟩), endotoxin testing (USP ⟨85⟩), and routine visual inspection of every CSP before release.